Neuronal Activity, Mitogens, and mTOR: Overcoming the Hurdles for the Treatment of Glioblastoma Multiforme

Glioblastoma multiforme (GBM) and other malignant gliomas are considered to be the most prevalent of primary malignant brain tumors. The incidence of these tumors per year is reported as 4.13 per 100,000 individuals per year. The median survival time following the diagnosis of GBM is approximately f...

Descripción completa

Detalles Bibliográficos
Autor principal: Maiese, Kenneth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482477/
https://www.ncbi.nlm.nih.gov/pubmed/26120474
_version_ 1782378447305179136
author Maiese, Kenneth
author_facet Maiese, Kenneth
author_sort Maiese, Kenneth
collection PubMed
description Glioblastoma multiforme (GBM) and other malignant gliomas are considered to be the most prevalent of primary malignant brain tumors. The incidence of these tumors per year is reported as 4.13 per 100,000 individuals per year. The median survival time following the diagnosis of GBM is approximately fifteen months in the setting of providing presently available treatments with surgical resection, radiation, and chemotherapy. Given these statistics, new strategies for the treatment of GBM and other aggressive tumors of the brain are warranted.
format Online
Article
Text
id pubmed-4482477
institution National Center for Biotechnology Information
language English
publishDate 2015
record_format MEDLINE/PubMed
spelling pubmed-44824772015-06-26 Neuronal Activity, Mitogens, and mTOR: Overcoming the Hurdles for the Treatment of Glioblastoma Multiforme Maiese, Kenneth J Transl Sci Article Glioblastoma multiforme (GBM) and other malignant gliomas are considered to be the most prevalent of primary malignant brain tumors. The incidence of these tumors per year is reported as 4.13 per 100,000 individuals per year. The median survival time following the diagnosis of GBM is approximately fifteen months in the setting of providing presently available treatments with surgical resection, radiation, and chemotherapy. Given these statistics, new strategies for the treatment of GBM and other aggressive tumors of the brain are warranted. 2015-06-01 2015 /pmc/articles/PMC4482477/ /pubmed/26120474 Text en http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Article
Maiese, Kenneth
Neuronal Activity, Mitogens, and mTOR: Overcoming the Hurdles for the Treatment of Glioblastoma Multiforme
title Neuronal Activity, Mitogens, and mTOR: Overcoming the Hurdles for the Treatment of Glioblastoma Multiforme
title_full Neuronal Activity, Mitogens, and mTOR: Overcoming the Hurdles for the Treatment of Glioblastoma Multiforme
title_fullStr Neuronal Activity, Mitogens, and mTOR: Overcoming the Hurdles for the Treatment of Glioblastoma Multiforme
title_full_unstemmed Neuronal Activity, Mitogens, and mTOR: Overcoming the Hurdles for the Treatment of Glioblastoma Multiforme
title_short Neuronal Activity, Mitogens, and mTOR: Overcoming the Hurdles for the Treatment of Glioblastoma Multiforme
title_sort neuronal activity, mitogens, and mtor: overcoming the hurdles for the treatment of glioblastoma multiforme
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482477/
https://www.ncbi.nlm.nih.gov/pubmed/26120474
work_keys_str_mv AT maiesekenneth neuronalactivitymitogensandmtorovercomingthehurdlesforthetreatmentofglioblastomamultiforme

Ejemplares similares